
EquitySector - HealthcareVery High Risk
Regular
NAV (22-May-26)
Returns (Since Inception)
Fund Size
₹530 Cr
Expense Ratio
2.09%
ISIN
INF251K01UY7
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+0.18%
— (Cat Avg.)
| Equity | ₹515.8 Cr | 97.28% |
| Others | ₹14.41 Cr | 2.72% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹49.73 Cr | 9.38% |
| Lupin Ltd | Equity | ₹32.27 Cr | 6.09% |
| Ipca Laboratories Ltd | Equity | ₹28.32 Cr | 5.34% |
| Abbott India Ltd | Equity | ₹27.98 Cr | 5.28% |
| Torrent Pharmaceuticals Ltd | Equity | ₹27.2 Cr | 5.13% |
| Laurus Labs Ltd | Equity | ₹25.32 Cr | 4.78% |
| Fortis Healthcare Ltd | Equity | ₹23.07 Cr | 4.35% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹22.91 Cr | 4.32% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.48 Cr | 4.24% |
| AstraZeneca Pharma India Ltd | Equity | ₹21.35 Cr | 4.03% |
| Emcure Pharmaceuticals Ltd | Equity | ₹18.24 Cr | 3.44% |
| SBI Life Insurance Co Ltd | Equity | ₹18.19 Cr | 3.43% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹15.77 Cr | 2.97% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹15.29 Cr | 2.88% |
| ICICI Prudential Life Insurance Co Ltd | Equity | ₹14.9 Cr | 2.81% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹14.44 Cr | 2.72% |
| Aurobindo Pharma Ltd | Equity | ₹13.9 Cr | 2.62% |
| Dr. Lal PathLabs Ltd | Equity | ₹13.67 Cr | 2.58% |
| Gland Pharma Ltd | Equity | ₹11.1 Cr | 2.09% |
| Divi's Laboratories Ltd | Equity | ₹10.99 Cr | 2.07% |
| Ajanta Pharma Ltd | Equity | ₹9.88 Cr | 1.86% |
| Acutaas Chemicals Ltd | Equity | ₹9.35 Cr | 1.76% |
| Medplus Health Services Ltd | Equity | ₹8.72 Cr | 1.64% |
| Inventurus Knowledge Solutions Ltd | Equity | ₹8.27 Cr | 1.56% |
| Nephrocare Health Services Ltd | Equity | ₹7.94 Cr | 1.50% |
| Concord Biotech Ltd | Equity | ₹6.85 Cr | 1.29% |
| Mankind Pharma Ltd | Equity | ₹6.74 Cr | 1.27% |
| Dr Reddy's Laboratories Ltd | Equity | ₹6.61 Cr | 1.25% |
| Metropolis Healthcare Ltd | Equity | ₹5.96 Cr | 1.12% |
| Cipla Ltd | Equity | ₹5.89 Cr | 1.11% |
| Poly Medicure Ltd | Equity | ₹5.76 Cr | 1.09% |
| Procter & Gamble Health Ltd | Equity | ₹5.74 Cr | 1.08% |
| Max Financial Services Ltd | Equity | ₹5.55 Cr | 1.05% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹5.52 Cr | 1.04% |
| Cohance Lifesciences Ltd | Equity | ₹5.1 Cr | 0.96% |
| Net Receivables / (Payables) | Cash | ₹-0.88 Cr | 0.17% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.07 Cr | 0.01% |
Large Cap Stocks
26.69%
Mid Cap Stocks
36.30%
Small Cap Stocks
34.28%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹467.81 Cr | 88.23% |
| Financial Services | ₹38.64 Cr | 7.29% |
| Basic Materials | ₹9.35 Cr | 1.76% |
Standard Deviation
This fund
--
Cat. avg.
16.62%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.99
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.77
Higher the better

Since June 2025

Since May 2026
ISIN INF251K01UY7 | Expense Ratio 2.09% | Exit Load 1.00% | Fund Size ₹530 Cr | Age 10 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹46,171 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments